Top 5 CRISPR Stocks To Invest In

In this article, we discuss the top 5 CRISPR stocks to invest in. If you want to read our discussion of the gene editing industry, head over to Top 11 CRISPR Stocks To Invest In. 

5. Exact Sciences Corporation (NASDAQ:EXAS)

Number of Hedge Fund Holders: 45

Exact Sciences Corporation (NASDAQ:EXAS) specializes in cancer screening and diagnostic test products, operating both in the United States and internationally. Their flagship product is Cologuard, a non-invasive stool-based DNA screening test designed to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It is one of the best gene editing stocks to invest in. 

On January 2, Benchmark upgraded Exact Sciences Corporation (NASDAQ:EXAS) stock to Buy and included it among its “best ideas” for 2024. The investment firm anticipates that Exact Sciences Corporation (NASDAQ:EXAS) will benefit from consistent growth in its core business, ongoing advancements in the new product pipeline, and a favorable interest rate environment. 

According to Insider Monkey’s third quarter database, 45 hedge funds were long Exact Sciences Corporation (NASDAQ:EXAS), same as the prior quarter. Ken Griffin’s Citadel Investment Group is a prominent stakeholder of the company, with 1.7 million shares worth $115.7 million. 

Artisan Small Cap Fund made the following comment about Exact Sciences Corporation (NASDAQ:EXAS) in its Q3 2023 investor letter:

“Among our top detractors were Lattice Semiconductor, Shockwave and Exact Sciences Corporation (NASDAQ:EXAS). Exact Sciences is a leading provider of diagnostic testing and maker of the noninvasive colorectal cancer screening test Cologuard®. The stock was a top performer through the first half of the year but pulled back in Q3. The company reported strong financial results as 31% growth in screening revenues (mostly Cologuard®) drove an overall 19% revenue increase. However, screening revenues fell slightly short of elevated expectations and were not good enough to support the stock’s year-to-date outperformance. We continue to be bullish on Cologuard’s® long-term growth potential; the addressable market expanded significantly in 2021 when the United States Preventive Services Task Force lowered the recommended age for colorectal cancer screenings to 45 from 50. Our research indicates the lowered screening age expands the company’s addressable market by ~18 million unscreened individuals. We also believe meaningful long term opportunities exist as the company develops additional high-value cancer tests.”